Edition:
United States

Avenue Therapeutics Inc (ATXI.OQ)

ATXI.OQ on NASDAQ Stock Exchange Capital Market

5.05USD
2:42pm EST
Change (% chg)

$-0.23 (-4.36%)
Prev Close
$5.28
Open
$5.28
Day's High
$5.28
Day's Low
$4.95
Volume
5,835
Avg. Vol
23,743
52-wk High
$6.00
52-wk Low
$2.10

Latest Key Developments (Source: Significant Developments)

Avenue Therapeutics Q3 Loss Per Share $0.25
Wednesday, 14 Nov 2018 04:30pm EST 

Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q3 LOSS PER SHARE $0.25.  Full Article

Avenue Therapeutics Reports Q4 Loss Per Share $0.63
Thursday, 1 Mar 2018 07:30am EST 

March 1 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q4 LOSS PER SHARE $0.63.  Full Article

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 08:00am EST 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Avenue Therapeutics reports Q3 loss per share $0.30
Thursday, 9 Nov 2017 07:30am EST 

Nov 9 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.30.  Full Article

Avenue Therapeutics doses first patient in postoperative pain trial
Wednesday, 27 Sep 2017 08:00am EDT 

Sept 27 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics announces dosing of first patient in pivotal Phase 3 clinical trial of intravenous tramadol for the management of postoperative pain.Avenue Therapeutics Inc says ‍expect to report topline data in Q2 of 2018​.Avenue Therapeutics Inc - about 405 patients will be enrolled to IV tramadol 50 mg, IV tramadol 25 mg or placebo in a 1:1:1 ratio​.  Full Article

Avenue Therapeutics shares open at $7.60 in debut vs. IPO price of $6.00/share
Tuesday, 27 Jun 2017 10:11am EDT 

June 27 (Reuters) - :Avenue Therapeutics Inc shares open at $7.60 in debut on the NASDAQ versus IPO price of $6.00 per share.  Full Article

BRIEF-Avenue Therapeutics prices IPO of $33 mln of common stock (June 26)
Tuesday, 27 Jun 2017 09:49am EDT 

Corrects source to Avenue Therapeutics from Fortress Biotech:Avenue Therapeutics prices initial public offering of $33,000,000 of common stock.Says initial public offering of 5.50 million common shares priced at $6.00per share.  Full Article

Avenue Therapeutics sees IPO priced between $5-$7/shr
Friday, 23 Jun 2017 06:25am EDT 

June 23 (Reuters) - Avenue Therapeutics Inc ::Avenue Therapeutics Inc sees IPO of 5.0 million shares of common stock to be priced between $5 and $7 per share - SEC filing.Avenue Therapeutics Inc says estimate net proceeds from sale of shares of common stock in IPO will be about $30.0 million.Avenue Therapeutics Inc plans to use about $16 million of IPO proceeds to fund continued clinical research, development initiatives in connection with IV Tramadol.Avenue Therapeutics Inc plans to use about $6 million of IPO proceeds to pay off debts to Fortress and NSC.  Full Article

Avenue Therapeutics says effective immediately, Lucy Lu, will serve as co's CEO
Friday, 2 Jun 2017 09:10am EDT 

June 2 (Reuters) - Avenue Therapeutics Inc :Says effective immediately, Lucy Lu, will serve as co's chief executive officer and president.  Full Article